Search

Your search keyword '"Malerba, Lara"' showing total 42 results
Start Over Author "Malerba, Lara"
42 results on '"Malerba, Lara"'

1. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, Milic, Natasa, Chatzikonstantinou, Thomas, Scarfò, Lydia, Otasevic, Vladimir, Rajovic, Nina, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Baile Gonzales, Monica, Capasso, Antonella, Collado, Rosa, Cordoba, Raul, Cuéllar-García, Carolina, Correa, Juan Gonzalo, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Dimou, Maria, Doubek, Michael, Efstathopoulou, Maria, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Lopez-Garcia, Alberto, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicińska, Elżbieta, Kater, Arnon P., Kersting, Sabina, Koren-Michowitz, Maya, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Fresa, Alberto, Levin, Mark-David, Mayor Bastida, Carlota, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mihaljevic, Biljana, Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Nunes, Raquel, Olivieri, Jacopo, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Reda, Gianluigi, Rigolin, Gian Matteo, Shrestha, Amit, Šimkovič, Martin, Smirnova, Svetlana, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Te Raa, Doreen, Tomic, Kristina, Tonino, Sanne, Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Vukovic, Vojin, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, Segundo, Lucrecia Yáñez San, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Carrier, Marc, Ghia, Paolo, and Stamatopoulos, Kostas

Published
2022
Full Text
View/download PDF

2. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfò, Lydia, Karakatsoulis, Georgios, Allsup, David, Cabrero, Alejandro Alonso, Andres, Martin, Antic, Darko, Baile, Mónica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuéllar-García, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Fürstenau, Moritz, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, Glenthøj, Andreas, Gomes da Silva, Maria, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Оlga B., Kalicińska, Elżbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, San Segundo, Lucrecia Yáñez, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2021
Full Text
View/download PDF

4. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, and Ghia, Paolo

Published
2020
Full Text
View/download PDF

5. The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

Author

Visentin, Andrea, primary, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Minga, Eva, additional, Chamou, Dimitra, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Antic, Darko, additional, Baile, Mónica, additional, Baliakas, Panagiotis, additional, Besikli‐Dimou, Sotiria, additional, Bron, Dominique, additional, Chatzileontiadou, Sofia, additional, Cordoba, Raul, additional, Correa, Juan‐Gonzalo, additional, Cuéllar‐García, Carolina, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Delgado, Julio, additional, Dimou, Maria, additional, Donaldson, David, additional, Catherwood, Mark, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, Eichhorst, Barbara, additional, Elashwah, Salma, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Frederiksen, Henrik, additional, Fürstenau, Moritz, additional, García‐Marco, José A., additional, García‐Serra, Rocío, additional, Collado, Rosa, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Glenthøj, Andreas, additional, da Silva, Maria Gomes, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández‐Rivas, José Ángel, additional, Herold, Tobias, additional, Innocenti, Idanna, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark‐David, additional, Lista, Enrico, additional, Lopez‐Garcia, Alberto, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca R., additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Niemann, Carsten U., additional, Rodrigues, Raquel Nunes, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Qvist, Kristian, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Tadmor, Tamar, additional, Capasso, Antonella, additional, Del Poeta, Giovanni, additional, Gutwein, Odit, additional, Karlsson, Linda Katharina, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Reda, Gianluigi, additional, Saghumyan, Gevorg, additional, Shrestha, Amit, additional, Te Raa, Doreen, additional, Tonino, Sanne H., additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, van Kampen, Roel, additional, Wasik‐Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Pocali, Barbara, additional, Vandenberghe, Elisabeth, additional, Iyengar, Sunil, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Cuneo, Antonio, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2023
Full Text
View/download PDF

6. Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.

Author

Autore, Francesco, Innocenti, Idanna, Reda, Gianluigi, Visentin, Andrea, Vitale, Candida, Piciocchi, Alfonso, Fresa, Alberto, Leone, Monica M. A., Farina, Lucia, Quaresmini, Giulia, Baratè, Claudia, Giordano, Annamaria, Ferrari, Angela, Angeletti, Ilaria, De Paolis, Maria Rosaria, Malerba, Lara, Chiurazzi, Federico, Loseto, Giacomo, Catania, Gioacchino, and Sportoletti, Paolo

Subjects
CHRONIC lymphocytic leukemia, VENETOCLAX, PROGRESSION-free survival, LYMPHADENITIS, LYMPHATIC metastasis, MULTIVARIATE analysis, CHRONIC leukemia
Abstract

Clinical or biological parameters useful to predict progression during treatment in real‐life setting with ibrutinib, idelalisib and venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) are still debated. We conducted a multi‐center retrospective study on CLL patients treated with ibrutinib and/or idelalisib who were switched to venetoclax for progression or due to adverse events to identify any clinical and/or biological parameters useful to predict progression during treatment with venetoclax. Of all the 128 evaluable patients, 81 had received ibrutinib prior to switching to venetoclax, 35 had received idelalisib and 12 both. When comparing the three subgroups, we did not notice any statistical difference in terms of clinical or biological features. No variable at baseline and at different time points during the follow‐up (at 6, 12, 18 and 24 months) was found to predict progression nor to have significance for Progression Free Survival (PFS) in the ibrutinib group and in the idelalisib group and in subgroups according to the line of treatment. Analyzing the data of the venetoclax treatment, after a median follow up of 14.3 months, median PFS was not reached and estimated 3‐year PFS was 54%. Of the 128 patients treated with venetoclax, 28 (22%) experienced progressive disease. At multivariate analysis for predictive factors for progression, lymph node diameter >56.5 mm before starting treatment emerged as an independent risk factor for progression. The lymph node predictive role for progression during venetoclax treatment could be a new parameter that deserves to be investigate in future studies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

7. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfò, Lydia, Karakatsoulis, Georgios, Allsup, David, Cabrero, Alejandro Alonso, Andres, Martin, Antic, Darko, Baile, Mónica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuéllar-García, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Fürstenau, Moritz, García-Marco, José A., García-Serra, Rocío, Gentile, Massimo, Gimeno, Eva, Glenthøj, Andreas, Gomes da Silva, Maria, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Hernández-Rivas, José Ángel, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Оlga B., Kalicińska, Elżbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Mirás, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Šimkovič, Martin, Špaček, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van Der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wróbel, Tomasz, San Segundo, Lucrecia Yáñez, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foà, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p< 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2024
Full Text
View/download PDF

8. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, primary, Scarfò, Lydia, additional, Chatzikonstantinou, Thomas, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Andres, Martin, additional, Antic, Darko, additional, Allsup, David, additional, Baile, Mónica, additional, Bron, Dominique, additional, Capasso, Antonella, additional, Catherwood, Mark, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Delgado, Julio, additional, Dimou, Maria, additional, Doubek, Michael, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Efstathopoulou, Maria, additional, Shimaa, El-Ashwah, additional, Enrico, Alicia, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Furstenau, Moritz, additional, Garcia-Marco, Jose A., additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Maria, Gomes da Silva, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernandez, jose Angel, additional, Herold, Tobias, additional, Iyengar, Sunil, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Olga, additional, Kalicinska, Elzbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark-David, additional, Lista, Enrico, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet Palomanes, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca Romana, additional, Mayor-Bastida, Carlota, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Milosevic, Ivana, additional, Miras Calvo, Fatima, additional, Niemann, Carsten Utoft, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Pocali, Barbara, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Raa, Doreen te, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca Ciocan, Oana, additional, Tadmor, Tamar, additional, Vandenberghe, Elisabeth, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Van Der Spek, Ellen, additional, Van Gelder, Michel, additional, Wasik-Szczepanek, Ewa, additional, Yáñez, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Eichhorst, Barbara, additional, Rambaldi, Alessandro, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional

Published
2022
Full Text
View/download PDF

9. Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Author

Antic, Darko, primary, Milic, Natasa, additional, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Otasevic, Vladimir, additional, Rajovic, Nina, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Baile Gonzales, Monica, additional, Capasso, Antonella, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Correa, Juan Gonzalo, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Dimou, Maria, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Lopez-Garcia, Alberto, additional, Garcia-Marco, Jose A., additional, García-Serra, Rocío, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Gomes da Silva, Maria, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernández-Rivas, José Ángel, additional, Herold, Tobias, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Koren-Michowitz, Maya, additional, Gomez, Jorge Labrador, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Fresa, Alberto, additional, Levin, Mark-David, additional, Mayor Bastida, Carlota, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Nunes, Raquel, additional, Olivieri, Jacopo, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Stavroyianni, Niki, additional, Te Raa, Doreen, additional, Tomic, Kristina, additional, Tonino, Sanne, additional, Trentin, Livio, additional, Van Der Spek, Ellen, additional, van Gelder, Michel, additional, Varettoni, Marzia, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Vukovic, Vojin, additional, Wasik-Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Yanez San Segundo, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Carrier, Marc, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2022
Full Text
View/download PDF

10. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Author

Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, Ghia, Paolo, Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, and Ghia, Paolo

Published
2022

11. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and COVID-19: A study of ERIC, the European Research Initiative on CLL

Author

Antic, Darko, primary, Milic, Natasa, additional, Chatzikonstantinou, Thomas, additional, Scarfò, Lydia, additional, Otasevic, Vladimir, additional, Rajovic, Nina, additional, Allsup, David, additional, Cabrero, Alejandro Alonso, additional, Andres, Martin, additional, Gonzales, Monica Baile, additional, Capasso, Antonella, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Correa, Juan Gonzalo, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Poeta, Giovanni Del, additional, Dimou, Maria, additional, Doubek, Michael, additional, Efstathopoulou, Maria, additional, El-Ashwah, Shaimaa, additional, Enrico, Alicia, additional, Espinet, Blanca, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Lopez-Garcia, Alberto, additional, García-Marco, José A., additional, García-Serra, Rocío, additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Silva, Maria Gomes, additional, Gutwein, Odit, additional, Hakobyan, Yervand K., additional, Herishanu, Yair, additional, Hernández-Rivas, José Ángel, additional, Herold, Tobias, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Оlga B., additional, Kalicińska, Elżbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Koren-Michowitz, Maya, additional, Gomez, Jorge Labrador, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Fresa, Alberto, additional, Levin, Mark-David, additional, Bastida, Carlota Mayor, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet, Juan, additional, Mihaljevic, Biljana, additional, Milosevic, Ivana, additional, Mirás, Fatima, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Nunes, Raquel, additional, Olivieri, Jacopo, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Smirnova, Svetlana, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca, Oana, additional, Stavroyianni, Niki, additional, Raa, Doreen Te, additional, Tomic, Kristina, additional, Tonino, Sanne, additional, Trentin, Livio, additional, Spek, Ellen Der, additional, Gelder, Michel, additional, Varettoni, Marzia, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Vukovic, Vojin, additional, Wasik-Szczepanek, Ewa, additional, Wróbel, Tomasz, additional, Segundo, Lucrecia Yáñez San, additional, Yassin, Mohamed, additional, Coscia, Marta, additional, Rambaldi, Alessandro, additional, Montserrat, Emili, additional, Foà, Robin, additional, Cuneo, Antonio, additional, Carrier, Marc, additional, Ghia, Paolo, additional, and Stamatopoulos, Kostas, additional

Published
2022
Full Text
View/download PDF

12. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report

Author

Cuneo, Antonio, primary, Rigolin, Gian Matteo, additional, Coscia, Marta, additional, Quaresmini, Giulia, additional, Scarfò, Lydia, additional, Mauro, Francesca Romana, additional, Motta, Marina, additional, Quaglia, Francesca Maria, additional, Trentin, Livio, additional, Ferrario, Andrea, additional, Laurenti, Luca, additional, Reda, Gianluigi, additional, Ferrari, Angela, additional, Pietrasanta, Daniela, additional, Sportoletti, Paolo, additional, Re, Francesca, additional, De Paoli, Lorenzo, additional, Foglietta, Myriam, additional, Giordano, Annamaria, additional, Marchetti, Monia, additional, Farina, Lucia, additional, Del Poeta, Giovanni, additional, Varettoni, Marzia, additional, Chiurazzi, Federico, additional, Marasca, Roberto, additional, Malerba, Lara, additional, Ibatici, Adalberto, additional, Tisi, Maria Chiara, additional, Stefoni, Vittorio, additional, Leone, Monica, additional, Baratè, Claudia, additional, Olivieri, Jacopo, additional, Murru, Roberta, additional, Gentile, Massimo, additional, Sanna, Alessandro, additional, Gozzetti, Alessandro, additional, Gattei, Valter, additional, Gottardi, Daniela, additional, Derenzini, Enrico, additional, Levato, Luciano, additional, Orsucci, Lorella, additional, Penna, Giuseppa, additional, Chiarenza, Annalisa, additional, and Foà, Robin, additional

Published
2021
Full Text
View/download PDF

13. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Author

Chatzikonstantinou, Thomas Kapetanakis, Anargyros Scarfo, Lydia and Karakatsoulis, Georgios Allsup, David Alonso Cabrero, Alejandro Andres, Martin Antic, Darko Baile, Monica and Baliakas, Panagiotis Bron, Dominique Capasso, Antonella and Chatzileontiadou, Sofia Cordoba, Raul Correa, Juan-Gonzalo and Cuellar-Garcia, Carolina De Paoli, Lorenzo De Paolis, Maria Rosaria Del Poeta, Giovanni Demosthenous, Christos Dimou, Maria Donaldson, David Doubek, Michael Efstathopoulou, Maria and Eichhorst, Barbara El-Ashwah, Shaimaa Enrico, Alicia and Espinet, Blanca Farina, Lucia Ferrari, Angela Foglietta, Myriam Frederiksen, Henrik Furstenau, Moritz Garcia-Marco, Jose A. Garcia-Serra, Rocio Gentile, Massimo Gimeno, Eva and Glenthoj, Andreas da Silva, Maria Gomes Gutwein, Odit and Hakobyan, Yervand K. Herishanu, Yair Angel Hernandez-Rivas, Jose and Herold, Tobias Innocenti, Idanna Itchaki, Gilad Jaksic, Ozren Janssens, Ann Kalashnikova, Olga B. Kalicinska, Elzbieta Karlsson, Linda Katharina Kater, Arnon P. Kersting, Sabina Labrador, Jorge Lad, Deepesh Laurenti, Luca and Levin, Mark-David Lista, Enrico Lopez-Garcia, Alberto and Malerba, Lara Marasca, Roberto Marchetti, Monia Marquet, Juan Mattsson, Mattias Mauro, Francesca R. Milosevic, Ivana and Miras, Fatima Morawska, Marta Motta, Marina Munir, Talha and Murru, Roberta Niemann, Carsten U. Rodrigues, Raquel Nunes and Olivieri, Jacopo Orsucci, Lorella Papaioannou, Maria and Arturo Pavlovsky, Miguel Piskunova, Inga Popov, Viola Maria and Quaglia, Francesca Maria Quaresmini, Giulia Qvist, Kristian and Reda, Gianluigi Rigolin, Gian Matteo Ruchlemer, Rosa and Saghumyan, Gevorg Shrestha, Amit Simkovic, Martin Spacek, Martin Sportoletti, Paolo Stanca, Oana Stavroyianni, Niki and Tadmor, Tamar Te Raa, Doreen Tonino, Sanne H. Trentin, Livio Van der Spek, Ellen van Gelder, Michel van Kampen, Roel Varettoni, Marzia Visentin, Andrea Vitale, Candida and Wasik-Szczepanek, Ewa Wrobel, Tomasz Yanez San Segundo, Lucrecia and Yassin, Mohamed Coscia, Marta Rambaldi, Alessandro and Montserrat, Emili Foa, Robin Cuneo, Antonio Stamatopoulos, Kostas Ghia, Paolo

Abstract

Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

Published
2021

15. Worldwide Examination of Patients with CLL Hospitalized for COVID-19

Author

Roeker, Lindsey E, Scarfo, Lydia, Chatzikonstantinou, Thomas, Abrisqueta, Pau, Eyre, Toby A., Cordoba, Raul, Muntañola Prat, Ana, Villacampa, Guillermo, Leslie, Lori A., Koropsak, Michael, Quaresmini, Giulia, Allan, John N., Furman, Richard R., Bhavsar, Erica B, Pagel, John M., Hernandez-Rivas, Jose Angel, Patel, Krish, Motta, Marina, Bailey, Neil, Miras, Fatima, Lamanna, Nicole, Alonso, Rosalia, Osorio-Prendes, Santiago, Vitale, Candida, Kamdar, Manali, Baltasar, Patricia, Österborg, Anders, Hanson, Lotta, Baile, Mónica, Rodríguez-Hernández, Ines, Valenciano, Susana, Popov, Viola Maria, Barez Garcia, Abelardo, Alfayate, Ana, Oliveira, Ana C, Eichhorst, Barbara, Quaglia, Francesca M., Reda, Gianluigi, Lopez Jimenez, Javier, Varettoni, Marzia, Marchetti, Monia, Romero, Pilar, Riaza Grau, Rosalía, Munir, Talha, Zabalza, Amaya, Janssens, Ann, Niemann, Carsten U, Perini, Guilherme Fleury, Delgado, Julio, Yanez San Segundo, Lucrecia, Gómez Roncero, Ma Isabel, Wilson, Matthew, Patten, Piers, Marasca, Roberto, Iyengar, Sunil, Seddon, Amanda, Torres, Ana, Ferrari, Angela, Cuéllar-García, Carolina, Wojenski, Daniel, El-Sharkawi, Dima, Itchaki, Gilad, Parry, Helen, Mateos-Mazón, Juan José, Martinez-Calle, Nicolas, Ma, Shuo, Naya, Daniel, Van Der Spek, Ellen, Seymour, Erlene K., Gimeno Vázquez, Eva, Rigolin, Gian Matteo, Mauro, Francesca Romana, Walter, Harriet S, Labrador, Jorge, De Paoli, Lorenzo, Laurenti, Luca, Ruiz, Elena, Levin, Mark-David, Šimkovič, Martin, Špaček, Martin, Andreu, Rafa, Walewska, Renata, Perez-Gonzalez, Sonia, Sundaram, Suchitra, Wiestner, Adrian, Cuesta, Amalia, Broom, Angus, Kater, Arnon P., Muiña, Begoña, Velasquez, César A, Ujjani, Chaitra S., Seri, Cristina, Antic, Darko, Bron, Dominique, Vandenberghe, Elisabeth, Chong, Elise A., Lista, Enrico, García, Fiz Campoy, Del Poeta, Giovanni, Ahn, Inhye, Pu, Jeffrey J., Brown, Jennifer R, Soler Campos, Juan Alfonso, Malerba, Lara, Trentin, Livio, Orsucci, Lorella, Farina, Lucia, Villalon, Lucia, Vidal, Maria Jesus, Sanchez, Maria Jose, Terol, Maria Jose, De Paolis, Maria Rosaria, Gentile, Massimo, Davids, Matthew S., Shadman, Mazyar, Yassin, Mohamed A, Foglietta, Myriam, Jaksic, Ozren, Sportoletti, Paolo, Barr, Paul M., Ramos, Rafael, Santiago, Raquel, Ruchlemer, Rosa, Kersting, Sabina, Huntington, Scott F., Herold, Tobias, Herishanu, Yair, Thompson, Meghan C., Lebowitz, Sonia, Ryan, Christine, Jacobs, Ryan W., Portell, Craig A., Isaac, Krista, Rambaldi, Alessandro, Nabhan, Chadi, Brander, Danielle M., Montserrat, Emili, Rossi, Giuseppe, Garcia-Marco, Jose A., Sr., Coscia, Marta, Malakhov, Nikita, Fernandez-Escalada, Noemi, Skånland, Sigrid Strand, Coombs, Callie C., Ghione, Paola, Schuster, Stephen J., Foà, Robin, Cuneo, Antonio, Bosch, Francesc, Stamatopoulos, Kostas, Ghia, Paolo, Mato, Anthony R., and Patel, Meera

Published
2020
Full Text
View/download PDF

17. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia:a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Author

Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, Ghia, Paolo, Scarfò, Lydia, Chatzikonstantinou, Thomas, Rigolin, Gian Matteo, Quaresmini, Giulia, Motta, Marina, Vitale, Candida, Garcia-Marco, Jose Antonio, Hernández-Rivas, José Ángel, Mirás, Fatima, Baile, Mónica, Marquet, Juan, Niemann, Carsten U., Reda, Gianluigi, Munir, Talha, Gimeno, Eva, Marchetti, Monia, Quaglia, Francesca Maria, Varettoni, Marzia, Delgado, Julio, Iyengar, Sunil, Janssens, Ann, Marasca, Roberto, Ferrari, Angela, Cuéllar-García, Carolina, Itchaki, Gilad, Špaček, Martin, De Paoli, Lorenzo, Laurenti, Luca, Levin, Mark David, Lista, Enrico, Mauro, Francesca R., Šimkovič, Martin, Van Der Spek, Ellen, Vandenberghe, Elisabeth, Trentin, Livio, Wasik-Szczepanek, Ewa, Ruchlemer, Rosa, Bron, Dominique, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Farina, Lucia, Foglietta, Myriam, Gentile, Massimo, Herishanu, Yair, Herold, Tobias, Jaksic, Ozren, Kater, Arnon P., Kersting, Sabina, Malerba, Lara, Orsucci, Lorella, Popov, Viola Maria, Sportoletti, Paolo, Yassin, Mohamed, Pocali, Barbara, Barna, Gabor, Chiarenza, Annalisa, dos Santos, Gimena, Nikitin, Eugene, Andres, Martin, Dimou, Maria, Doubek, Michael, Enrico, Alicia, Hakobyan, Yervand, Kalashnikova, Olga, Ortiz Pareja, Macarena, Papaioannou, Maria, Rossi, Davide, Shah, Nimish, Shrestha, Amit, Stanca, Oana, Stavroyianni, Niki, Strugov, Vladimir, Tam, Constantine, Zdrenghea, Mihnea, Coscia, Marta, Stamatopoulos, Kostas, Rossi, Giuseppe, Rambaldi, Alessandro, Montserrat, Emili’, Foà, Robin, Cuneo, Antonio, and Ghia, Paolo

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79–7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Published
2020

23. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma

Author

Visani, Giuseppe, Stefani, Pietro Maria, Capria, Saveria, Malerba, Lara, Galieni, Piero, Gaudio, Francesco, Specchia, Giorgina, Meloni, Giovanna, Gherlinzoni, Filippo, Gonella, Roberta, Gobbi, Marco, Santoro, Armando, Ferrara, Felicetto, Rocchi, Marco, Ocio, Enrique M., Caballero, Maria Dolores, Loscocco, Federica, and Isidori, Alessandro

Published
2014
Full Text
View/download PDF

26. Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study

Author

Offidani, Massimo, primary, Maracci, Laura, additional, Corvatta, Laura, additional, Anna Marina, Liberati, additional, Ballanti, Stelvio, additional, Attolico, Imma, additional, Caraffa, Patrizia, additional, Alesiani, Francesco, additional, Caravita di Toritto, Tommaso, additional, Gentili, Silvia, additional, Tosi, Patrizia, additional, Brunori, Marino, additional, Derudas, Daniele, additional, Ledda, Antonio, additional, Gozzetti, Alessandro, additional, Cellini, Claudia, additional, Malerba, Lara, additional, Mele, Anna, additional, Felici, Stefano, additional, Galimberti, Sara, additional, Mondello, Patrizia, additional, Pulini, Stefano, additional, Coppetelli, Ugo, additional, Fraticelli, Paolo, additional, Rizzi, Rita, additional, and Leoni, Pietro, additional

Published
2014
Full Text
View/download PDF

27. Bendamustine, Bortezomib and Dexamethasone (BVD): A Combination With a Substantial Activity and a Manageable Toxicity In Patients With Relapsed-Refractory Multiple Myeloma (MM)

Author

Offidani, Massimo, primary, Corvatta, Laura, additional, Maracci, Laura, additional, Liberati, Anna Marina, additional, Ballanti, Stelvio, additional, Attolico, Immacolata, additional, Caraffa, Patrizia, additional, Alesiani, Francesco, additional, Caravita di Toritto, Tommaso, additional, Gentili, Silvia, additional, Tosi, Patrizia, additional, Brunori, Marino, additional, Derudas, Daniele, additional, Ledda, Antonio, additional, Gozzetti, Alessandro, additional, Cellini, Claudia, additional, Malerba, Lara, additional, Mele, Anna, additional, Andriani, Alessandro, additional, Galimberti, Sara, additional, Mondello, Patrizia, additional, Pulini, Stefano, additional, Coppetelli, Ugo, additional, Fraticelli, Paolo, additional, Olivieri, Attilio, additional, and Leoni, Pietro, additional

Published
2013
Full Text
View/download PDF

28. Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Followed By Autologous Stem Cell Transplantation Produce a 3-Year Progression-Free Survival Of 75% In Heavily Pre-Treated Hodgkin and Non-Hodgkin Lymphoma

Author

Visani, Giuseppe, primary, Stefani, Pietro Maria, additional, Capria, Saveria, additional, Malerba, Lara, additional, Galieni, Piero, additional, Gaudio, Francesco, additional, Specchia, Giorgina, additional, Meloni, Giovanna, additional, Gherlinzoni, Filippo, additional, Giardini, Claudio, additional, Falcioni, Sadia, additional, Gonella, Roberta, additional, Cuberli, Francesca, additional, Gobbi, Marco, additional, Sarina, Barbara, additional, Santoro, Armando, additional, Ferrara, Felicetto, additional, Rocchi, Marco, additional, Ocio, Enrique M., additional, Caballero, Maria Dolores, additional, Picardi, Paola, additional, Ricciardi, Teresa, additional, Loscocco, Federica, additional, and Isidori, Alessandro, additional

Published
2013
Full Text
View/download PDF

29. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Author

Visani, Giuseppe, primary, Malerba, Lara, additional, Stefani, Pietro Maria, additional, Capria, Saveria, additional, Galieni, Piero, additional, Gaudio, Francesco, additional, Specchia, Giorgina, additional, Meloni, Giovanna, additional, Gherlinzoni, Filippo, additional, Giardini, Claudio, additional, Falcioni, Sadia, additional, Cuberli, Francesca, additional, Gobbi, Marco, additional, Sarina, Barbara, additional, Santoro, Armando, additional, Ferrara, Felicetto, additional, Rocchi, Marco, additional, Ocio, Enrique M., additional, Caballero, Maria Dolores, additional, and Isidori, Alessandro, additional

Published
2011
Full Text
View/download PDF

30. Thalidomide, Dexamethasone, Doxil and Velcade (ThaDD-V) Induction Therapy Followed by Consolidation/Maintenance Is Very Effective In Early Relapsed/Refractory MM

Author

Offidani, Massimo, primary, Polloni, Claudia, additional, Corvatta, Laura, additional, Gentili, Silvia, additional, Mele, Anna, additional, Brunori, Marino, additional, Rizzi, Rita, additional, Catarini, Massimo, additional, Samori, Arduino, additional, Blasi, Nicola, additional, Ferranti, Mario, additional, Malerba, Lara, additional, Caraffa, Patrizia, additional, and Leoni, Pietro, additional

Published
2010
Full Text
View/download PDF

31. A Novel High Dose Chemotherapy Strategy with Bendamustine In Adjunct to Etoposide, Cytarabine and Melphalan (BeEAM) Followed by Autologous Stem Cell Rescue Is Safe and Highly Effective for the Treatment of Resistant/Relapsed Lymphoma Patients: a Phase I-II Study on 44 Patients

Author

Visani, Giuseppe, primary, Malerba, Lara, additional, Stefani, Pietro Maria, additional, Capria, Saveria, additional, Galieni, Piero, additional, Gaudio, Francesco, additional, Specchia, Giorgina, additional, Meloni, Giovanna, additional, Gherlinzoni, Filippo, additional, Giardini, Claudio, additional, Falcioni, Sadia, additional, Loscocco, Federica, additional, Cuberli, Francesca, additional, Gobbi, Marco, additional, Santoro, Armando, additional, Sarina, Barbara, additional, Rocchi, Marco, additional, and Isidori, Alessandro, additional

Published
2010
Full Text
View/download PDF

33. Role of Previous Thalidomide Administration on Final Outcome for 72 Patients with Relapsed Multiple Myeloma (MM) Treated with Bortezomib–Based Therapy

Author

Offidani, Massimo, primary, Corvatta, Laura, primary, Polloni, Claudia, primary, Piersantelli, Maria-Novella, primary, Gentili, Silvia, primary, Ruggieri, Miriana, primary, Malerba, Lara, primary, Alesiani, Francesco, primary, Catarini, Massimo, primary, Brunori, Marino, primary, Samori, Arduino, primary, Burattini, Maurizio, primary, Minnucci, Luisa, primary, Mele, Anna, primary, Marconi, Monica, primary, and Leoni, Pietro, primary

Published
2008
Full Text
View/download PDF

34. An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab

Author

Visani, Giuseppe, primary, Mele, Anna, additional, Guiducci, Barbara, additional, D'adamo, Francesca, additional, Leopardi, Giuliana, additional, Barulli, Sara, additional, Malerba, Lara, additional, Lucesole, Moira, additional, Sparaventi, Giovanni, additional, Piccaluga, Pier Paolo, additional, Guernaccini, Elena, additional, Agostinelli, Fabrizio, additional, and Isidori, Alessandro, additional

Published
2006
Full Text
View/download PDF

40. Autologous Stem Cell Transplantation for Aggressive Lymphomas.

Author

Visani, Giuseppe, Picardi, Paola, Tosi, Patrizia, Gonella, Roberta, Loscocco, Federica, Ricciardi, Teresa, Malerba, Lara, Guiducci, Barbara, Tomassetti, Simona, Barulli, Sara, and Isidori, Alessandro

Subjects
STEM cell transplantation, LYMPHOMA treatment, B cells, HODGKIN'S disease, T cells, SALVAGE therapy, DISEASE relapse
Abstract

The role of high-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) in the treatment armamentarium of aggressive B- and T-cell non-Hodgkin lymphoma (NHL) is still a matter of debate. In the pre-Rituximab era, the PARMA study demonstrated the superiority of HDT/ASCT over conventional salvage chemotherapy in chemosensitive, relapsed patients. Subsequently, HDT/ASCT has become a standard approach for relapsed NHL. With the advent of Rituximab in the landscape of NHL, transplantation as part of first-line therapy has been challenged. However, no benefit in terms of disease-free or overall survival of HDT/ASCT over standard therapy was shown when Rituximab was added to both arms. Moreover, the superiority of HDT/ASCT over conventional salvage therapy in patients relapsing from first-line therapy including Rituximab was not confirmed. From these disappointing results, novel strategies, which can enhance the anti-lymphoma effect, at the same time reducing toxicity have been developed, with the aim of improving the outcome of HDT/ASCT in aggressive NHL. In T-cell lymphoma, few publications demonstrated that consolidation of complete remission with HDT/ASCT is safe and feasible. However, up to one-third of patients may never receive transplant, mostly due to progressive disease, and relapse still remains a major concern even after transplant. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

41. High-dose daunorubicin as liposomal compound (Daunoxome(registered)) in elderly patients with acute lymphoblastic leukemia1.

Author

Offidani, Massimo, Corvatta, Laura, Centurioni, Riccardo, Leoni, Franco, Malerba, Lara, Mele, Anna, Marconi, Monica, Scortechini, Annarita, Cristiana Masia, M, and Leoni, Pietro

Subjects
*LIPOSOMES, *LYMPHOBLASTIC leukemia, *HEMATOLOGY
Abstract

Elderly acute lymphoblastic leukemia (ALL) is a rare condition associated with low complete remission (CR) rate and short survival. In order to improve these results, we evaluate the efficacy and toxicity of Daunoxome(registered), a liposomal daunorubicin, exhibiting toxicity profile and pharmacokinetic indices better than standard daunorubicin. In total, 15 consecutive patients with nonmature ALL were enrolled on a prospective phase II study. No exclusion was made because of older age, poor performance status and organ dysfunctions. Median age was 69 years; performance status resulted ?2 in nine patients (60%), six patients (40%) were bcr-abl positive and two-thirds of the patients had comorbidities. Induction therapy consisted of vincristine, Daunoxome(registered) and dexamethasone. Patients in CR received one or two consolidation cycles of cyclophosphamide, cytarabine and topotecan followed, in patients achieving CR, by a two-year rotating maintenance course including vincristine, Daunoxome(registered), cyclophosphamide and prednisone. In all, 11 patients (73%) achieved CR, three patients (20%) died early during the induction phase and one patient (7%) had resistant disease. Five patients (33%) relapsed after 5-21 months. With a median follow-up of 20 months, disease free survival (DFS) and overall survival (OS) at 2 years were 36 and 38%, respectively. Major toxicity included myelosuppression and infection. Our experience demonstrates that a high dose of daunorubicin as liposomal compound can be safely administered in elderly ALL, exhibiting high antitumor activity. Our therapeutic program shows evidence of benefit in DFS and OS.The Hematology Journal (2003) 4, 47-53. doi:10.1038/sj.thj.6200222 [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

42. Advancement in high dose therapy and autologous stem cell rescue in lymphoma.

Author

Isidori A, Clissa C, Loscocco F, Guiducci B, Barulli S, Malerba L, Gabucci E, and Visani G

Abstract

Although advanced stage aggressive non-Hodgkin's lymphomas and Hodgkin's disease are thought to be chemotherapy-responsive cancers, a considerable number of patients either relapse or never attain a remission. High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is often the only possibility of cure for most of these patients. However, many controversial issues still remain with respect to HDT/ASCT for lymphomas, including its role for, the optimal timing of transplantation, the best conditioning regimen and the potential use of localized radiotherapy or immunologic methods to decrease post-transplant recurrence. Recently, mainly due to the unavailability of carmustine, several novel conditioning protocols have been clinically developed, with the aim of improving the overall outcome by enhancing the anti-lymphoma effect and, at the same time, by reducing short and long-term toxicity. Furthermore, the better safety profiles of novel approaches would definitively allow patients aged more than 65-70 years to benefit from this therapeutic option. In this review, we will briefly discuss the most relevant and recent data available regarding HDT/ASCT in lymphomas.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results